Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [522]
News [1466]
Articles [67]
Editorials [2]
Conferences [72]
elearning [5]
Investigational immunotherapy drug combo safe with early signs of effectiveness...
Dr David Bajor - University of Pennsylvania, Philadelphia, USA
Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma ( Dr David Bajor - University of Pennsylvania, Philadelphia, USA )
29 Apr 2015
Chk1 inhibition combined with standard dose gemcitabine may be safe and...
Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA
Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )
29 Apr 2015
Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
27 Apr 2015
Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial
Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
27 Apr 2015
BRAF 'behind the scenes' in melanoma: A scientific story of discovery
Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK
BRAF 'behind the scenes' in melanoma: A scientific story of discovery ( Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK )
19 Mar 2015
Connecting science, practice and patient outcomes: Use of BRAF inhibitors for...
Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium
Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice ( Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium )
19 Mar 2015
Response and resistance with BRAF inhibitors: Mechanisms, markers and...
Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA
Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions ( Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA )
19 Mar 2015
ecancermedicalscience editor's choice for February 2015
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
3 Mar 2015
New approaches and new partnership models for biomarker based clinical research
Dr Denis Lacombe, EORTC, Brussels, Belgium
New approaches and new partnership models for biomarker based clinical research ( Dr Denis Lacombe, EORTC, Brussels, Belgium )
6 Jan 2015
Aims and successes of the 2nd EurocanPlatform project translational research...
Christina von Gertten, Karolinska Institutet, Stockholm, Sweden
Aims and successes of the 2nd EurocanPlatform project translational research course ( Christina von Gertten, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015
Epigenome deregulation in cancer
Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon...
Epigenome deregulation in cancer ( Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France )
6 Jan 2015
Immunotherapy of cancer: recent progress and future challenges
Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden
Immunotherapy of cancer: recent progress and future challenges ( Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation